Role for a water-soluble form of CoQ10 in female subjects affected by fibromyalgia. A preliminary study
Decreased antioxidant capacity and increased oxidative stress have been observed in fibromyalgia patients. Some trials have also shown that CoQ10 levels are reduced in these patients but that supplementation can restore levels and reduce fibromyalgia symptoms, including pain and fatigue. We evaluated the effect of administration of a finished form of CoQ10 (DDM Chinone®) at a dose of 200 mg×2/day in 22 female subjects with a diagnosis of fibromyalgia in a randomized, open-label, cross-over study. Our results show that, compared to a control group, administration of CoQ10 significantly improved most pain-related outcomes by 24-37%, including fatigue (by ~22%) and sleep disturbance (by ~33%). These results confirm the considerable role played by CoQ10 in reducing pain, fatigue, and sleep disturbance in subjects affected by fibromyalgia.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:35 Suppl 105 |
|---|---|
| Enthalten in: |
Clinical and experimental rheumatology - 35 Suppl 105(2017), 3 vom: 14. Mai, Seite 20-27 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Di Pierro, Francesco [VerfasserIn] |
|---|
| Themen: |
1339-63-5 |
|---|
| Anmerkungen: |
Date Completed 31.08.2017 Date Revised 31.08.2017 published: Print-Electronic Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM267127863 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM267127863 | ||
| 003 | DE-627 | ||
| 005 | 20231224220014.0 | ||
| 007 | tu | ||
| 008 | 231224s2017 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n0890.xml |
| 035 | |a (DE-627)NLM267127863 | ||
| 035 | |a (NLM)27974102 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Di Pierro, Francesco |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Role for a water-soluble form of CoQ10 in female subjects affected by fibromyalgia. A preliminary study |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 31.08.2017 | ||
| 500 | |a Date Revised 31.08.2017 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Decreased antioxidant capacity and increased oxidative stress have been observed in fibromyalgia patients. Some trials have also shown that CoQ10 levels are reduced in these patients but that supplementation can restore levels and reduce fibromyalgia symptoms, including pain and fatigue. We evaluated the effect of administration of a finished form of CoQ10 (DDM Chinone®) at a dose of 200 mg×2/day in 22 female subjects with a diagnosis of fibromyalgia in a randomized, open-label, cross-over study. Our results show that, compared to a control group, administration of CoQ10 significantly improved most pain-related outcomes by 24-37%, including fatigue (by ~22%) and sleep disturbance (by ~33%). These results confirm the considerable role played by CoQ10 in reducing pain, fatigue, and sleep disturbance in subjects affected by fibromyalgia | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 7 | |a Vitamins |2 NLM | |
| 650 | 7 | |a Ubiquinone |2 NLM | |
| 650 | 7 | |a 1339-63-5 |2 NLM | |
| 650 | 7 | |a coenzyme Q10 |2 NLM | |
| 650 | 7 | |a EJ27X76M46 |2 NLM | |
| 700 | 1 | |a Rossi, Alessandra |e verfasserin |4 aut | |
| 700 | 1 | |a Consensi, Arianna |e verfasserin |4 aut | |
| 700 | 1 | |a Giacomelli, Camillo |e verfasserin |4 aut | |
| 700 | 1 | |a Bazzichi, Laura |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical and experimental rheumatology |d 1989 |g 35 Suppl 105(2017), 3 vom: 14. Mai, Seite 20-27 |w (DE-627)NLM012613010 |x 0392-856X |7 nnns |
| 773 | 1 | 8 | |g volume:35 Suppl 105 |g year:2017 |g number:3 |g day:14 |g month:05 |g pages:20-27 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 35 Suppl 105 |j 2017 |e 3 |b 14 |c 05 |h 20-27 | ||